Human immunodeficiency virus type 1 (HIV-1) fusion with its target cells is initiated by sequential interactions between its envelope glycoprotein, CD4, and a co-receptor, usually CCR5 or CXCR4. Small molecules that bind to CCR5 and prevent its use by R5 HIV-1 strains are now being developed clinically as antiviral drugs. To test whether a block to CCR5 promotes the replication of viruses that enter cells via CXCR4 and are associated with accelerated disease progression, we administered a small molecule CCR5 inhibitor, CMPD 167, to three macaques dual-infected with both R5 (SIVmac251) and X4 (SHIV-89.6P) viruses. CMPD 167 caused a rapid and substantial (on average, 50-fold) suppression of R5 virus replication in each animal. In two of the animals, but not in the third, a rapid, transient, 8-to 15-fold increase in the amount of plasma X4 virus occurred. In neither animal was the increase in X4 viral load sustained throughout therapy, however. These observations may have relevance for the development of CCR5 inhibitors for treatment of HIV-1 infection of humans. D
Introduction
CCR5 is a 7-transmembrane G-protein coupled receptor for CC-chemokines that is also used as an entry coreceptor by human immunodeficiency virus type 1 (HIV-1) (Berger et al., 1999; Clapham and McKnight, 2002; Doms, 2001; Schwarz and Wells, 2002) . Most new HIV-1 infections involve the transmission or early dominance of viruses that use CCR5 (R5 strains), but HIV-1 can also use another coreceptor, the CXC-chemokine receptor CXCR4 (Berger et al., 1999; Clapham and McKnight, 2002; Doms, 2001; Schwarz and Wells, 2002) . CXCR4-using viruses (X4 strains) are only rarely transmitted, but if they emerge during infection, the disease course is accelerated Richman and Bozzette, 1994; Schuitemaker et al., 1992) . One reason is that X4 viruses are inherently more cytopathic than R5 strains (Grivel et al., 2000; Etemad-Moghadam et al., 2001) , another is that they target naive CD4
+ T-cells both in the periphery and in the thymus, thereby also impairing T-cell production (Douek et al., 2003; Hazenberg et al., 2000; McCune, 2001) .
Entry inhibitors are an emerging class of drugs to treat HIV-1 infection, and the first of them, Enfuvirtide (T-20) has recently been licensed as a drug (Kilby and Eron, 2003; Moore and Doms, 2003) . One sub-class of entry inhibitors comprises small molecules that bind to CCR5 and block its coreceptor function, several of which are now in clinical development (Kazmierski et al., 2003; Kilby and Eron, 2003; Meanwell and Kadow, 2003; Moore and Doms, 2003; Schwarz and Wells, 2002; Sobieszczyk et al., 2004; Strizki et al., 2001) . A long-standing concern with the clinical use of CCR5 inhibitors is that they might indirectly promote the replication of X4 strains and hence exacerbate disease (Berger et al., 1999; Clapham and McKnight, 2002; Doms, 2001; Michael and Moore, 1999; Moore et al., 2004) . This could occur by the mutation of R5 viruses to favor CXCR4 use, although in vitro studies suggest that coreceptor switching is not the usual escape pathway driven by the small molecule inhibitors (Kuhmann et al., 2004; Trkola et al., 2002) (JPM et al., unpublished results) . Alternatively, R5 viruses appear to suppress the replication of X4 viruses under in vivo conditions (Harouse et al., 2003) , so inhibition of R5 virus entry might simply allow the expansion of preexisting X4 strains without the need for genetic interconversion of an R5 virus to an X4 variant (Harouse et al., 2003; Moore et al., 2004) .
To address these issues, particularly the latter, we have used a non-human primate model. Specifically, rhesus macaques were dual-infected with both R5 (SIVmac251) and X4 (SHIV-89.6P) viruses for 3 months until viral set points were established, and then treated with a CCR5-specific small molecule inhibitor, CMPD 167. We have previously shown that CMPD 167 suppresses SIV replication in vitro and in vivo (Veazey et al., 2003) , but like other CCR5 inhibitors, it has no effect on SHIV-89.6P replication (Veazey et al., 2003; Zhang et al., 2000) . We found in the present study that CMPD 167 caused a rapid and substantial (on average, 50-fold) suppression of R5 virus replication in each test animal. In two of the dualinfected animals, but not in the third, a rapid, transient, 8-to 15-fold increase in the amount of plasma X4 virus occurred. In neither animal was the increase in X4 viral load sustained throughout therapy.
Results

Simultaneous quantification of R5 and X4 viral loads in dual-infected animals
To be able to study the effect of a CCR5 inhibitor on both R5 and X4 components of the total viral load in dualinfected animals, it is necessary to quantify both viruses simultaneously. We therefore developed a set of discriminatory, real-time kinetic RT-PCR assays, using stringencymatched primers based on the 5V-ends of the env genes of SIVmac251 and SHIV-89.6P, and on a conserved region of SIV gag. Thus, the env-based assays each detect only one of the viruses, the gag-based assay detects both, because both viruses contain the SIV gag gene.
A central feature of the assays is their use of an internal control RNA transcript as a standard to allow accurate determination of the copy number of each viral target. The control transcript was created by end-to-end ligation of 500-nt fragments of SIVmac251 env, SHIV-89.6P env, and SIV gag and insertion of the 1500-nt construct into vector pCR2.1. We evaluated the specificity and sensitivity of the final assay and established that we could routinely quantify a low or negative copy number of one viral RNA even in the presence of a substantial excess (N10 7 -fold) of the other (data not shown).
Dual-infection of a Chinese rhesus macaque
An initial experiment involving a Chinese rhesus macaque infected simultaneously with both SIVmac251 and SHIV-89.6P demonstrated that both infecting viruses could indeed be quantified simultaneously using a discriminatory viral load assay. In this pilot study, we used an earlier generation version of the assay that had separate, and not interlinked, internal control transcripts, but we judge the results to be broadly comparable to those derived using the later-generation assay described above. In the test animal, the levels of SIVmac251 and SHIV-89.6P viral load 60-90 days post-infection were found to be in the ranges 10 4 -10 5 and 10 3 -10 4 RNA copies/ml, respectively, an R5-X4 ratio of approximately 10. Macaques of Chinese origin sustain lower viral loads than those of Indian origin, and the rate of disease progression is also reduced, so the viral loads we measured are not unexpected (Ling et al., 2002) . Of note was that the sum of the measurements of the SIVmac251 and SHIV-89.6P env genes equaled the total value for SIV gag, within the same log range (data not shown). Because both infecting viruses contain the SIVmac251 gag gene, this concordance attests to the appropriate performance of the discriminatory viral load assay.
Dual-infection of Indian rhesus macaques, and effect of CMPD 167 on viral load in a SIVmac251-infected animal Two Indian rhesus macaques (AN15 and BEO8) were simultaneously inoculated intravenously with SIVmac251 and SHIV-89.6P; two others (T369 and P137) were superchallenged with SHIV-89.6P 8 months after intravaginal SIVmac251 infection. Following dual infection, all four macaques were monitored for 11 weeks so that a stable viral bset pointQ was established. The final generation discriminatory assay was used to monitor viral loads for the next 100-220 days.
One of the monkeys, P137, became infected with SIVmac251 only, with no detection of SHIV-89.6P at any time point. The viral load in this animal was quantified using both the SIV env-and gag-based assays; there was excellent concordance between the two measurements of absolute and relative changes (Fig. 1 ). The baseline plasma viremia level was in the range 2-4 Â 10 5 RNA copies/ml (Fig. 1) . CMPD 167 was administered intravenously to P137 using the same protocol that we had shown to cause viral load reductions in other SIVmac251-infected animals (Veazey et al., 2003) . Thus, P137 received CMPD 167 intravenously twice-daily for 14 days, then once-daily for a further 14 days, the dosing reduction being IACUCmandated to reduce the cumulative exposure of test animals to anesthesia.
A rapid and substantial reduction (2.0-2.3 log 10 ) in viral load occurred in P137 upon the initiation of CMPD 167 therapy, with a nadir being reached between days 6 and 8 (Fig. 1 ). There was a gradual rebound after dosing was switched from twice-to once-daily on day 14. By the end of the 28 days of therapy, viral load had returned approximately to baseline, probably because of the sub-optimal nature of therapy during the last 14 days; it remained near the baseline value for the rest of the monitoring period (105 days). There was no significant change in CD4 count in P137 during therapy; it remained fairly stable at approximately 400 cells/Al (Fig. 2b) . Overall, the plasma viremia response to CMPD 167 in P137 was broadly consistent with what we observed in six other SIV-infected macaques (Veazey et al., 2003) .
The other three animals, AN15, BE08, and T369, clearly became infected with both challenge viruses (Figs. 2-4). Total viral loads (gag-based assay) were in the range 10 5 to 10 7 RNA copies/ml by 50 days post-inoculation (Fig. 2a) . The ratio of the SIVmac251 and SHIV-89.6P viral loads varied between 2.3 (T369) and 29 (AN15) at baseline (Fig.  3 , Table 1 ). This is consistent with a previous report that the R5 viral load was always the higher in macaques dualinfected with R5 and X4 SHIVs (Harouse et al., 2003) , and with our observations in the dual-infected Chinese rhesus macaque (see above).
The CD4 counts were very low in two of the three dualinfected animals, but were preserved at an intermediate level in T369 (Fig. 2b) . SHIV-89.6P infection usually ablates CD4 counts very rapidly, with peak SHIV-89.6P viremia during primary infection predicting subsequent CD4 T cell loss (Igarashi et al., 2003; Zhang et al., 2004) . It is notable that T369 had the lowest absolute SHIV-89.6P viral load of the three dual-infected animals during primary infection (Fig. 3b) .
Effects of CMPD 167 on viral load in dual-infected animals
When CMPD 167 was administered intravenously to the three dual-infected macaques, there was a rapid and substantial decrease in SIVmac251 virus load in each of the animals (Figs. 3 and 4). In AN15 and T369, the maximum reductions were 25-and 40-fold, respectively, reached by days 9-13, with the viral loads subsequently rebounding after the switch to once-daily dosing, as had been observed in the single-infected animal, P137 (Figs. 1,3 ). The SIVmac251 viral load decline was slower but more sustained in animal BE08, the nadir being a 50-fold reduction on day 23 (Fig. 3c ). Despite daily observations and minimal clinical signs, this monkey was found dead 3 weeks after the end of therapy. Necropsy revealed cryptosporidiosis (consistent with AIDS) as well as severe amyloidosis and chronic endometriosis, the latter two diseases appear to have been chronic in duration (both diseases are common in primates). Viral load determinations for BE08 from the last few days of therapy and post-therapy were not made using the finalgeneration assay as too little blood was available, and so are not plotted. However, the use of an earlier generation, less precise assay had indicated that the trends shown in Fig. 3c continued unchanged until the last sample, which was taken on day 40 (data not shown).
Upon initiation of CMPD 167 therapy, the SHIV-89.6P viral load increased substantially and rapidly in AN15 and T369, reaching levels 11-fold and 7.5-fold higher than baseline after 5 days (Figs. 3a,b) . However, this elevation in the X4 component of the total viral load was only transient. In both animals, X4 viral load began to decline on day 8, and in T369 it was below baseline from day 9 onward. In AN15, Fig. 1 . Effect of CMPD 167 on viral load in SIVmac 251-infected monkey P137. The RNA copy number/ml plasma is shown as a function of time (days). Time 0 marks the start of CMPD 167 therapy, which was given twice daily for 14 days, then once daily for a further 14 days. Viral load was measured using a SIVmac251-gag ( ) or env ( ) assay. a smaller, second blip in X4 virus load occurred between approximately days 15 and 25 (Fig. 3a) . The doubling times of the initial X4 viral load increases in AN15 and T369 were 1.1 and 1.3 days, respectively, comparable with the t 1/2 values for the R5 viral load declines (Table 1 ). In the third dual-infected animal, BE08, there was no increase in SHIV-89.6P viral load during CMPD 167 therapy (Fig. 3c) . After therapy ceased, the X4 viral load was little or no higher than the pre-therapy level in any of the three animals (Fig. 3) . The total viral load, measured using the gag-based assay, fluctuated only a little during therapy in all three animals because it represents the sum of the changing SIVmac251 and SHIV-89.6P viral loads (Fig. 2a) . Thus, at early times, the decrease in SIVmac251 viral load was countered by an increase in SHIV-89.6P viremia, dampening the overall decline in total viral load (Fig. 2a, Fig. 3 ).
To better study the kinetics of changes, the R5 and X4 viral loads during therapy were expressed relative to the baseline values (=1.0) (Fig. 4) . The X4 viral load peak in AN15 and T369 was reached slightly earlier than the trough of the R5 decline, and the decline from the X4 peak occurred while the R5 viral load was still suppressed, or even falling. The R5/X4 viral load ratios varied markedly during therapy, but a substantial decrease in the ratio occurred at the time of the X4 viral load peak (Table 1) . At this time, the R5 viral loads were 9-and 40-fold lower than the X4 viral loads in AN15 and T369, respectively. By the time CMPD 167 therapy ceased, however, the R5/X4 ratios were considerably higher than pre-therapy values (Table 1) , and fluctuated at higher levels throughout the rest of the monitoring period.
No significant changes in CD4 + T-cell counts in the two animals with very low baseline counts were observed during CMPD 167 therapy (Fig. 2b) . Animal T369 had maintained an intermediate level of cells at the start of the CMPD 167 treatment period. During therapy, the CD4 + T-cell counts in T369 trended downwards, but they diminished much more sharply once therapy ceased (Fig. 2b) . A similar pattern of changes in CD4 + T-cell count was observed in the SIVmac251 single-infected animal P136 during and after CMPD 167 treatment. Thus, although T369 was one of the was no change in total blood monocyte count in any of the animals during therapy (data not shown).
Discussion
An obvious limitation of this study is the limited number of dual-infected animals we have been able to study to date, which restricts the certainty of any conclusions that can be drawn. Within that constraint, our principal observation is that the suppression of R5 virus production by a CCR5 inhibitor in vivo was associated with an increase in X4 virus load in 2 of 3 dual-infected animals. However, this increase was only transient, and after 10 days of therapy, the X4 virus load was little or no greater than before therapy was initiated. In the third dual-infected animal, the CCR5 inhibitor had no effect on X4 virus load. In all three animals, plus the animal infected with SIVmac251 only, the R5 viral load was reduced significantly by the CCR5 inhibitor, at least during the period of optimal, twice-daily dosing. The t 1/2 values for the SIVmac251 viral load decline in the dual-infected animals (1.1-1.6 days; Table 1 ) were similar to values for singly infected animals in this (1.1 days, Table 1 ) and our previous study (average 0.94 F 0.18 days) (Veazey et al., 2003) . The mean maximum R5 viral load decrease in the dual-infected animals was 1.6 F 0.15 log 10 , identical to the decrease in the seven singly infected animals in this and the previous study (1.6 F 0.5 log 10 ). Thus the presence of an X4 virus does not impair the activity of a CCR5 inhibitor against an R5 virus in vivo. The SIVmac251 viral load reductions in the single-and dualinfected animals (1.6 log 10 ) are also comparable to the average viral load reductions seen during 10-day dosing trials of humans with other small molecule CCR5 inhibitors (1.50 log 10 for SCH-C at 100mg, BID; 1.62 log 10 for SCH-D at 50 mg BID; 1.42 log 10 for UK-427,857 at 100 mg, BID) (M. Laughlin, Schering Plough and C. Hitchcock, Pfizer, UK, personal communications). This concordance is noteworthy given the differences in the inhibitors, infecting viruses (SIV vs. HIV-1) and species between the various studies.
The overall patterns of R5 viral load responses to CMPD 167 in the dual-infected animals were consistent with ones we observed in SIV single-infected animals in this study (P137; Fig. 1 ) and in our previous one (Veazey et al., 2003) . The SIVmac251 viral load rebounds in animals AN15 and T369 during the later stages of CMPD 167 therapy again probably reflect the sub-optimal nature therapy during this period. Another possible explanation is the development of outright resistance to CMPD 167. The latter could be due to the acquisition either of the ability to use CCR5 despite the presence of the inhibitor, or of an increased capacity to use alternative, unidentified coreceptors, although probably not CXCR4 (Veazey et al., 2003; Zhang et al., 2000) .
How a reduction in R5 virus replication can lead to a transient increase in X4 viral load remains to be determined. The increase was very rapid, as quick as the decline in R5 viral load that is directly caused by the CCR5 inhibitor. Under the conditions of our study, it cannot represent mutation of the R5 SIVmac251 virus into an X4 variant, as the assay used to quantify the X4 viral load is specific for SHIV-89.6P. Nor is such a mutation likely to occur rapidly, given the general inability of SIV strains to use CXCR4 as a co-receptor (Berger et al., 1999; Clapham and McKnight, 2002; Doms, 2001; Moore et al., 2004; Schwarz and Wells, 2002) . Moreover, we have shown previously that CMPD 167 does not affect SHIV-89.6P replication in the absence of an R5 virus, in vitro or in vivo (Veazey et al., 2003) . It has been argued that R5 viruses might actively suppress the replication of X4 viruses, in both dual-infected humans and macaques (Harouse et al., 2003; Lee et al., 2000; . Our results are consistent with this hypothesis. Thus, we show that an X4 viral load increase can occur when both R5 and X4 viruses are present, and the R5 component is suppressed; pre-existing X4 viruses may therefore fill a niche vacated by the R5 strains, at least temporarily (Harouse et al., 2003; Moore et al., 2004) .
One possible mechanism for an interaction between R5 and X4 strains in vivo is that competition might occur between CXCR4 and CCR5 for a limiting amount of CD4 on the surface of some cells (Lee et al., 2000) . Such a mechanism would be most likely to operate when the cell surface CD4 density is low, as it is, for example, on macrophages (Lee et al., 2000; Lewin et al., 1996; Tokunaga et al., 2001 ). Thus, it has been shown that a CCR5-blocking chemokine, RANTES, can increase Env-mediated fusion via CXCR4 on human macrophages (Lee et al., 2000) . By extrapolation, perhaps blocking CCR5 with CMPD 167 renders more CD4-CXCR4 complexes available for an X4 virus to use. It may be relevant that, when an X4 SHIV has depleted most of the CD4 + T-cells from a macaque, most of the X4 viral load is derived from macrophages (Igarashi et al., 2001 (Igarashi et al., , 2002 . In passing, we note that this must presumably apply also to the production of SIVmac251 under the same circumstances because the dual-infected animals sustained very high levels of SIVmac251 replication despite, in two cases, having extremely low peripheral CD4 + T-cell counts (Fig. 2b) . It seems unlikely that changes in acquired immune responses could occur quickly enough to account for the rapid increase in X4 virus replication upon CMPD 167 administration. Alteration in innate immunity profiles, particularly levels of chemokines or pro-inflammatory cytokines, could, perhaps, occur quickly enough to be relevant. For example, if a CCR5 inhibitor somehow caused a decrease in SDF-1 expression that could in turn increase X4 virus production (Berger et al., 1999; Clapham and McKnight, 2002; Doms, 2001; Moore et al., 2004; Schwarz and Wells, 2002) . Another possibility is that the RANTESantagonist property of CMPD 167 might increase extracellular RANTES concentrations sufficiently for the latter to enhance the replication of X4 viruses, a phenomenon that can occur in vitro (Dolei et al., 1998; Gordon et al., 1999; Kinter et al., 1998; Trkola et al., 1999) . In vitro studies of the effects of chemokines on virus replication do have predictive limitations, however. Under in vitro conditions, for example, in lymphoid tissue blocks, the replication of X4 viruses is clearly dominant over that of R5 strains during dualinfection experiments (Grivel and Margolis, 1999; Grivel et al., 2000; Ito et al., 2004; Malkevitch et al., 2001) , whereas the converse situation appears to apply in vivo (Harouse et al., 2003; Michael and Moore, 2001; Moore et al., 2004) .
Although X4 viral load did increase after addition of CMPD 167 in two of the test animals, it then almost as rapidly declined. Again, the reasons are obscure, but one explanation might be that the highly cytopathic SHIV-89.6P virus quickly kills a pool of target cells that it was newly able to infect, perhaps a subset of tissue macrophages (Igarashi et al., 2001 (Igarashi et al., , 2002 Lee et al., 2000) . There were, however, no detectable changes in the counts of CD4 + Tcells or monocytes in the peripheral blood of the test animals during the period of CMPD 167 infusion (Fig. 2b , and data not shown). It is possible that target cell destruction occurred within other body compartments that we were not able to sample during this study.
We noted earlier that we have been able to study a small number of monkeys to date, and ones that are infected with a very aggressive X4 virus. Clearly, additional animals will need to be studied before we can draw definitive conclusions, and we will need to build into future experiments what we have learned from the present, exploratory one. Another limitation is that we are not addressing here the possible long-term evolution of an R5 virus into an X4 strain, either as an escape mechanism under the selection pressure of a CCR5 inhibitor, or spontaneously. Our focus in this study has been on the immediate responses of the R5 and X4 components of a mixed infection to perturbation by a CCR5 inhibitor. Based on in vitro studies, the most common mechanism of evolutionary escape from CCR5 inhibitors may also not involve switching to CXCR4 use (Kuhmann et al., 2004; Trkola et al., 2002) (JPM et al., unpublished results) . However, other escape pathways could incur risks associated with a broadening of viral tropism in vivo (Gorry et al., 2002; Kuhmann et al., 2004) .
Despite the caveats noted earlier, our results may still be relevant to the development of CCR5 inhibitors for human use (Kazmierski et al., 2003; Kilby and Eron, 2003; Meanwell and Kadow, 2003; Moore and Doms, 2003; Schwarz and Wells, 2002; Sobieszczyk et al., 2004; Strizki et al., 2001) . It is too early to know how such drugs would be used if they are licensed. One obvious strategy is to administer them only to individuals who have been screened to exclude the overt presence of X4 viruses . But it is clearly possible that CCR5 inhibitors might sometimes be given to individuals that harbor X4 viruses, perhaps at levels below the limit of detection of viral phenotype assays (Shankarappa et al., 1999) . There have, in fact, already been two examples of the administration of CCR5 inhibitors to humans who harbored detectable levels of X4 viruses (diagnosed retrospectively) during Phase I clinical trials. In one case, the X4 viral load increased as the R5 viral load declined over the scheduled 10-day dosing period with the CCR5 inhibitor. When therapy ceased, the X4 viral load rapidly reverted to baseline (C. Hitchcock, Pfizer, UK, personal communication). In the second case, the total viral load was reduced by approximately 0.5 log 10 during therapy then returned to baseline after therapy ceased; no information is yet available on whether specific changes in the X4 component occurred (M. Laughlin, Schering Plough, personal communication). It is clearly not possible to draw definitive conclusions from anecdotal observations in two humans, or from the limited numbers of macaques that we have been able to study to date. However, the transience of the X4 viral load increases in animals AN15 and T369 does suggest that any increased X4 virus production occurring when dual-infected humans are dosed with CCR5 inhibitors might not always be sustained, even if the therapy is maintained. Larger scale human clinical trials will presumably provide an answer to this question, one which is central to the practical development of CCR5 inhibitor therapy.
In any eventuality, CCR5 inhibitors will surely be combined with other, more traditional drugs to further suppress HIV-1 replication and minimize escape. Early reports from small scale studies suggest that conventional HAART is more effective against X4 than R5 viruses, which would tend to minimize the evolution of X4 strains under these conditions (Equils et al., 2000; Galan et al., 2004; Philpott et al., 2001) . Clearly, these complex issues will only be finally resolved by the conduct of carefully designed and thoroughly monitored human trials as the CCR5 inhibitors progress through clinical development. Macaque studies such as the one described here might help with the design and interpretation of such trials, as well as throwing light on the underlying virology and cell biology of primate immunodeficiency virus infection, particularly the usage of the CCR5 and CXCR4 coreceptors under in vivo conditions.
Methods
Real-time PCR assays for R5 and X4 viral loads
Three independent Taqman assays were developed to detect and quantify RNA molecules derived from the SIVmac251 gag, SIVmac251 env, or SHIV-89.6P env genes. Specifically, the following primers and probes were chosen based on the recommendations of the Primer Express (Applied Biosystems) application. For the SIVmac251 gag assay, the forward primer was SIV gag 61F, cca cct (ag)cc att aag ccc ga; the reverse primer was SIV gag 143R, ctg gca cta ctt ctg ctc caa a and the probe was SIV gag 84T FAM _ QSY, cat taa atg cct ggg taa aat tga tag agg a(ga)a aga a. For the SIVmac251 env assay, the forward primer was SIV251 env7F, tgt ctt ggg aat cag ctg ctt, the reverse primer was SIV251 env94R, cac cat aaa aga ctg tga cat att gag tac, and the probe was SIV-251 env30T FAM _ QSY, cgc cat ctt gct ttt aag tgt cta tgg gat cta t. For the SHIV-89.6P env assay, the forward primer was SHIV 89.6 env 53F, gca cca tgc tcc ttg gga t, the reverse primer was SHIV 89.6 env, 147R ggt tgc ttc tct cca cac agg t, and the probe was SHIV 89.6 env 85T FAM_QSY, agt gct aca gaa aaa ttg tgg gtc aca gtc tat tat gg.
Each probe was synthesized with FAM as the reporter dye and a dark dye quencher. Individual Taqman reactions were performed using the bOne step RT-PCR master mixQ from Applied Biosystems according to the manufacturer's recommended conditions, and with 3.3 pmol of each primer and 1.6 pmol of each probe. Cycling was performed on an Applied Biosystems 7900 Sequence Detector as follows: 50 8C for 30 min, then 95 8C for 10 min, followed by 45 cycles of 95 8C for 15 sec, and 60 8C for 1 min. Fluorescence data were collected at each step of the PCR cycle and were analyzed using the Applied Biosystems SDS2.1 software system. The linear range of amplification for all three assays was between 50 copies and 5 Â 10 7 RNA copies per ml of plasma. All assay results were reproducible, with little assay-to-assay discrepancy.
To make the internal control transcript for each target, approximately 500 base pairs surrounding the Taqman assay site were amplified by PCR from a pure viral stock.
Restriction sites were incorporated into the PCR primers to allow the three fragments to be ligated together. This construct of SIVmac2521 gag, SIVmac251 env, and SHIV-89.6P env was ligated into vector PCR2.1 (Invitrogen). After sequencing to determine the exact sequence and length of the insert, the vector was linearized and used as a template for RNA transcription from the T7 promoter. The resulting RNA transcripts were purified from the DNA vector, then quantified using a spectrophotometer quantified to measure the OD 260/280 ratio. Known amounts were used to generate the standard curves for quantification of each target, with the standards containing between 10 and 1 Â 10 8 input copies.
Infection of rhesus macaques and administration of CMPD 167
Macaques T369 and P137 were intravaginally inoculated with 640 TCID 50 of SIVmac251 and 8 months later, superinfected by intravenous inoculation with 20 TCID 50 of SHIV-89.6P. Macaques AN15 and BE08 were simultaneously intravenously infected with 100 TCID 50 of SIVmac251 and 20 TCID 50 of SHIV-89.6P on the same day the other animals were inoculated with SHIV-89.6P. Viral loads were monitored for 11 weeks after the dual challenge of all 4 macaques, until stable set points had been reached. The animals then received CMPD 167 (10 mg/kg) intravenously by bolus injection, twice-daily for 14 days, then once-daily for a further 14 days, the change being IACUC-mandated to minimize cumulative exposure to anesthesia (Veazey et al., 2003) . Plasma viral loads were monitored 1-2 times daily during treatment, then at least weekly for 6 weeks after therapy ceased. CD4 counts were determined as described previously (Veazey et al., 2003) .
